News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Conference News AHA 2024 Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression Yael L. Maxwell November 20, 2024
News Conference News AHA 2024 Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY Shelley Wood November 17, 2024
News Features GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix? Todd Neale November 13, 2024
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Daily News HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF L.A. McKeown October 01, 2024
News Daily News Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF Todd Neale September 20, 2024
News Conference News ESC 2024 Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER Todd Neale August 31, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News CMS Announces Negotiated Medicare Prices for First 10 Drugs Yael L. Maxwell August 16, 2024
News Daily News Scoring System Puts Focus on Medical Therapy Optimization in HFrEF L.A. McKeown August 13, 2024
News Conference News ESC Heart Failure 2024 Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show Michael O'Riordan May 21, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Opinion Off Script Evoque and Patisiran: A Tale of Two Regulatory Journeys Sanjay Kaul, MD March 29, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024